YOUR SEARCH FOR Text 261 RESULTS
152 of Total
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
153 of Total
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
154 of Total
Resources | Incyte
Investor Email Alerts RSS Feeds Investor FAQs Show All Where is Incyte located? Incyte's Global Headquarters is currently located at 1801
155 of Total
Resources | Incyte
Investor Email Alerts RSS Feeds Investor FAQs Clicking on an RSS link below will provide you with raw XML data of our content. If you do not have a
156 of Total
0000879169-24-000045 | 10-K | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-K Filing Date Feb 13, 2024 Document Date Dec 31, 2023 Form
157 of Total
0000879169-26-000010 | 10-K | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-K Filing Date Feb 10, 2026 Document Date Dec 31, 2025 Form
158 of Total
0001628280-25-004633 | 10-K | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-K Filing Date Feb 10, 2025 Document Date Dec 31, 2024 Form
159 of Total
0000879169-23-000016 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date May 2, 2023 Document Date Mar 31, 2023 Form
160 of Total
0000879169-23-000025 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date Aug 1, 2023 Document Date Jun 30, 2023 Form
A New Frontier
in Hematology
Incyte proudly adds VGA039 and the
VIVID study to its hematology portfolio.